Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com
Dr. Wadha A. Al-Muftah

Achievements

—Diabetes Genetics Research: Completed doctoral research at Imperial College London examining genetic, epigenetic, and environmental factors associated with type 2 diabetes in Qatari families.
—National Healthcare Strategy Contributions: Participated in healthcare-related committees and initiatives supporting biomedical education, research, and national health priorities.
—Leadership at Qatar Precision Health Institute (QPHI): Served in a senior medical and operational leadership role, supporting the advancement of precision health and genomic medicine.

Dr. Wadha A. Al-Muftah

Senior Director, Genome Program

Qatar Precision Health Institute

About

Dr. Wadha A. Al-Muftah, MD, PhD is a physician-scientist and precision-health leader in Qatar. She is one of the founding leaders of the Qatar Genome Programme and has played a major role in developing Qatar's national genomics and precision-health initiatives.

She has served as Senior Director of the Genome Program at the Qatar Precision Health Institute (QPHI), Qatar Foundation, where she has led strategic initiatives involving genomic medicine, genome interpretation, clinical implementation, and the responsible return of genomic findings. In this role, she has worked closely with organizations including Hamad Medical Corporation, Sidra Medicine, the Ministry of Public Health, and Primary Health Care Corporation.

Dr. Al-Muftah earned her PhD in Clinical Research from Imperial College London through the Qatar Research Leadership Program. Her doctoral research investigated the genetic, epigenetic, and environmental determinants of type 2 diabetes in Qatari families. Her scientific work has contributed to research in population genomics, diabetes, pharmacogenomics, and precision medicine.

As Senior Director of the Qatar Genome Programme, she has been involved in the development of one of the region's major population-genomics initiatives. At the launch of QPHI, she reported that the Qatar Genome Programme had surpassed 40,000 whole genomes sequenced, supporting research and the implementation of precision healthcare in Qatar.

She has also contributed to the integration of genomics into clinical practice, including projects investigating pharmacogenetic testing and its impact on cardiovascular medications and clinical implementation of preemptive pharmacogenomics-guided prescribing.

Dr. Wadha A. Al-Muftah, MD, PhD, is a Qatari physician-scientist and healthcare executive recognized for her contributions to genomics, precision medicine, and translational research. She is the Chief Medical and Operations Officer at Qatar Precision Health Institute (QPHI) and is one of the founding leaders of the Qatar Genome Programme. Her work focuses on translating genetic and genomic discoveries into practical healthcare applications, supporting personalized medicine, and advancing national precision-health strategies in Qatar.

With more than 15 years of experience in medical research and healthcare innovation, Dr. Al-Muftah has helped develop initiatives that connect genomic research with clinical practice. Her work includes genomic interpretation, pharmacogenomics, population-level genetic research, and the responsible communication of genomic findings to patients and healthcare professionals.

She collaborates with healthcare and research organizations, including the Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, and the Primary Health Care Corporation. Her professional contributions aim to improve disease prevention, diagnosis, and treatment by incorporating genetic information into healthcare decision-making.

Current Institution and Leadership Position

Qatar Precision Health Institute (QPHI), Qatar

  • Chief Medical and Operations Officer.
  • Physician-scientist and healthcare executive.
  • Founding leader of the Qatar Genome Programme.
  • Former senior leader in the Qatar Genome Programme, with responsibilities in applied genomics and translational research.

Education and Qualifications

  • Doctor of Medicine (MD) — Arabian Gulf University, Bahrain, 2005.
  • PhD in Clinical Research — Imperial College London, United Kingdom, 2016.
  • Executive Leadership Programme — HEC Paris, France.

Her doctoral research examined genetic, epigenetic, and environmental factors associated with type 2 diabetes in Qatari families.

Career and Professional Experience

Qatar Precision Health Institute

As Chief Medical and Operations Officer, Dr. Al-Muftah contributes to the institute's strategic direction and operational leadership. Her work focuses on translating scientific discoveries into healthcare applications, supporting partnerships, and advancing precision-health initiatives across Qatar.

Qatar Genome Programme

Dr. Al-Muftah has played a central role in developing the Qatar Genome Programme, a large-scale initiative investigating the genetic characteristics of the Qatari population and their implications for health.

Her responsibilities have included strategic planning, genomic research, genome interpretation, and initiatives to incorporate clinically relevant genetic findings into medical practice.

Translational Genomics and Clinical Implementation

Her work has involved developing frameworks for genomic interpretation and clinical reporting, as well as supporting projects that integrate genomic discoveries into healthcare pathways. These initiatives help clinicians use genetic information to support diagnosis, treatment selection, and disease-risk assessment.

Pharmacogenomics and Personalized Medicine

Dr. Al-Muftah has helped advance pharmacogenomics research in Qatar. Pharmacogenomics examines how genetic differences influence a person's response to medicines and can support more individualized medication selection and dosing.

Her work has included collaboration with national healthcare partners on studies exploring pharmacogenetic testing for cardiovascular medications.

Research Interests

  • Precision medicine and precision health
  • Human genetics and population genomics
  • Translational genomics
  • Pharmacogenomics and personalized drug therapy
  • Type 2 diabetes and metabolic disease
  • Genetic and epigenetic variation
  • Genomic screening and interpretation
  • Responsible return of genomic findings
  • Personalized disease prevention and treatment
  • Implementation of genomic medicine in healthcare systems

Selected Research Publications

1. Mendelian Inheritance of Trimodal CpG Methylation Sites Suggests Distal Cis-Acting Genetic Effects

This research examined inherited patterns of DNA methylation and their relationship with genetic regulation. It contributed to the understanding of epigenetic variation and its potential implications for human health.

2. PopPAnTe: Population and Pedigree Association Testing for Quantitative Data

This publication presented a methodological approach for genetic association testing using population and family-pedigree data, supporting research into the genetic factors underlying human traits.

3. Willingness to Participate in Genome Testing: A Survey of Public Attitudes from Qatar

This study examined public attitudes toward genomic testing in Qatar, providing evidence relevant to public engagement, consent, and the implementation of genomic medicine.

4. Mapping the Human Genetic Architecture of COVID-19

Dr. Al-Muftah contributed to collaborative research investigating genetic factors associated with COVID-19 susceptibility and severity. The research helped advance scientific understanding of host genetic variation and infectious disease outcomes.

5. Whole-Genome Sequencing in the Middle Eastern Qatari Population

Her broader research contributions include studies investigating genetic variation in the Qatari population and identifying associations between genomic characteristics and clinically relevant traits.

Major Achievements and Contributions

  1. Founding leadership of the Qatar Genome Programme: Contributed to the development of a major national genomics initiative.
  2. Advancement of precision health in Qatar: Helped connect genomic research with clinical applications and national healthcare priorities.
  3. Clinical implementation of genomic findings: Supported frameworks for interpreting and responsibly returning genetic results to patients and healthcare professionals.
  4. Pharmacogenomics research: Contributed to initiatives exploring how genetic information can improve medication selection and treatment safety.
  5. Research on type 2 diabetes: Conducted doctoral research on genetic, epigenetic, and environmental factors associated with diabetes in Qatari families.
  6. International scientific collaboration: Contributed to research published in international scientific journals and worked with researchers across multiple institutions.
  7. Healthcare leadership: Combines medical training, scientific research, and executive leadership to support the development of precision medicine.

Awards and Recognition

Dr. Al-Muftah's documented professional recognition includes her leadership positions in Qatar's national genomics and precision-health initiatives, her international research contributions, and her participation in scientific conferences and national health committees.

Specific named individual awards could not be reliably confirmed and are therefore not listed as established honors.

Major Achievements

  • Founding Leadership of the Qatar Genome Programme: Contributed to the development of Qatar’s national genomic research and precision medicine initiatives.
  • Leadership at Qatar Precision Health Institute (QPHI): Served in a senior medical and operational leadership role, supporting the advancement of precision health and genomic medicine.
  • Genomic Research and Interpretation: Contributed to projects involving genomic data interpretation and the responsible communication of clinically relevant genetic findings.
  • Diabetes Genetics Research: Completed doctoral research at Imperial College London examining genetic, epigenetic, and environmental factors associated with type 2 diabetes in Qatari families.
  • Pharmacogenomics: Contributed to research exploring how genetic variation can influence responses to medications, including cardiovascular treatments.
  • National Healthcare Strategy Contributions: Participated in healthcare-related committees and initiatives supporting biomedical education, research, and national health priorities.
  • Scientific Publications and Presentations: Contributed to scientific research and professional discussions in genomics, precision medicine, and translational healthcare.

Events & Activities

6th Annual MENA Metabolic & Genetic Conference (MGC2026)
May 14, 2026
In-Person

6th Annual MENA Metabolic & Genetic Conference (MGC2026)

Maarefah Management

  • DHA CME Credits
  • Dubai · JW Marriott Marquis Hotel, Dubai, UAE
May 14, 2026
In-Person

6th Annual MENA Metabolic & Genetic Conference (MGC2026)

USD 100

This medical conference and workshop is designed for a diverse audience of healthcare professionals, including physicians, residents, nurses, and allied health practitioners, offering a comprehensive learning and networking experience.

Maarefah Management

  • 3 Days
  • Dubai · JW Marriott Marquis Hotel, Dubai, UAE
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
Dr. Wadha A. Al-Muftah — Senior Director, Genome Program | MedArena